Wei Wang
Impact in
- Infectious Diseases top 0.5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Oncology top 0.5%
- COVID-19 and healthcare impacts
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Lung Cancer Diagnosis and Treatment 59
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 26
- Respiratory Support and Mechanisms 25
- Lung Cancer Treatments and Mutations 23
- Oncology 74
- Cancer Immunotherapy and Biomarkers 44
- Co-authors
- Jianxing He (53 shared papers)Wenhua Liang (26 shared papers)Hengrui Liang (25 shared papers)Wei‐jie Guan (4 shared papers)Caichen Li (6 shared papers)Jianfu Li (6 shared papers)Shiyue Li (4 shared papers)Ke Xu (4 shared papers)
- Journals
- Translational Lung Cancer Research (12 papers)Medicine (9 papers)PLoS ONE (9 papers)Frontiers in Oncology (8 papers)Oncotarget (7 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Wei Wang
403 papers receiving 14.5k citations
Wei Wang's Hit Papers
Peers
Comparison fields: 5 of 170
- Infectious Diseases 3.7k
- Oncology 3.9k
- General Dentistry 39
- Pulmonary and Respiratory Medicine 2.5k
- Cancer Research 1.1k
Countries citing papers authored by Wei Wang
This map shows the geographic impact of Wei Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Wang more than expected).
Fields of papers citing papers by Wei Wang
This network shows the impact of papers produced by Wei Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Wang. The network helps show where Wei Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 447 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Hit paper breakdown → | 2020 | 3339 |
| 2 | Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis Hit paper breakdown → | 2020 | 2702 |
| 3 | 2020 | 367 | |
| 4 | 2020 | 217 | |
| 5 | 2020 | 210 | |
| 6 | 2012 | 202 | |
| 7 | 2020 | 195 | |
| 8 | Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial Hit paper breakdown → | 2022 | 185 |
| 9 | 2010 | 170 | |
| 10 | Targeting PCDH20 gene by microRNA-122 confers 5-FU resistance in hepatic carcinoma. | 2016 | 154 |
| 11 | 2019 | 141 | |
| 12 | 2019 | 136 | |
| 13 | 2018 | 124 | |
| 14 | 2014 | 122 | |
| 15 | Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma ( NIC‐ESCC2019 ): A multicenter, phase 2 study Hit paper breakdown → | 2022 | 122 |
| 16 | 2021 | 117 | |
| 17 | 2015 | 106 | |
| 18 | 2013 | 103 | |
| 19 | 2020 | 94 | |
| 20 | 2016 | 85 |
About Wei Wang
Wei Wang is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Surgery and Infectious Diseases, having authored 447 papers that have together received 14.9k indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (59 papers), Cancer Immunotherapy and Biomarkers (44 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (26 papers), Respiratory Support and Mechanisms (25 papers), Lung Cancer Treatments and Mutations (23 papers), MicroRNA in disease regulation (22 papers), Esophageal Cancer Research and Treatment (19 papers) and COVID-19 Clinical Research Studies (11 papers). The work is most often cited by research in Infectious Diseases (3.7k citations), Oncology (3.9k citations), General Dentistry (39 citations), Pulmonary and Respiratory Medicine (2.5k citations) and Cancer Research (1.1k citations). Wei Wang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Jianxing He, Wenhua Liang, Hengrui Liang, Wei‐jie Guan, Caichen Li, Jianfu Li, Shiyue Li, Ke Xu, Ruchong Chen and Weixiang Lu. Their work appears in journals such as Translational Lung Cancer Research, Medicine, PLoS ONE, Frontiers in Oncology and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.